UK Markets open in 6 hrs 42 mins

Fresenius SE & Co. KGaA (FRE.DE)

XETRA - XETRA Delayed price. Currency in EUR
Add to watchlist
42.73-0.10 (-0.23%)
At close: 5:35PM CEST
Full screen
Previous close42.83
Open43.13
Bid42.79 x 120700
Ask42.78 x 6100
Day's range42.55 - 43.41
52-week range24.25 - 51.54
Volume1,221,606
Avg. volume1,825,052
Market cap28.317B
Beta (5Y monthly)1.17
PE ratio (TTM)13.03
EPS (TTM)3.28
Earnings date29 Oct 2020
Forward dividend & yield0.84 (1.99%)
Ex-dividend date31 Aug 2020
1y target estN/A
  • Looking for a Growth Stock? 3 Reasons Why Fresenius (FMS) is a Solid Choice
    Zacks

    Looking for a Growth Stock? 3 Reasons Why Fresenius (FMS) is a Solid Choice

    Fresenius (FMS) could produce exceptional returns because of its solid growth attributes.

  • Reuters

    Fresenius beats second-quarter earnings forecasts, cuts 2020 outlook

    The group said its separately listed dialysis unit, Fresenius Medical Care, showed very strong earnings growth and exceptional cash flow in the quarter. For 2020, Fresenius expects adjusted net income change between a negative 4% and a positive 1%, and revenue growth in the range of 3% to 6%, compared to its previous forecast for growth between 1% to 5% and 4% to 7%, respectively, which did not account for the pandemic's effects. Fresenius' second-quarter net income came in at 410 million euros ($482.6 million), above analysts' average forecast of 398 million euros, according to a company-provided poll.

  • Fresenius cuts 2020 outlook on pandemic impact
    Reuters

    Fresenius cuts 2020 outlook on pandemic impact

    In its first forecasts factoring in the impact of the pandemic, the company said it expected adjusted net income this year within a range of down 4% to up 1% from last year, and revenue growth of 3-6%. The pandemic has been a mixed blessing for healthcare companies, bringing increased demand for selected products and services but also delays in treatments and extra expenses. While the number of post-acute treatments should gradually recover, postponed site inspections will cut Fresenius' 2020 product launches by about 30% and project delays may last well into the second half, Sturm said.

By using Yahoo, you agree that we and our partners can use cookies for purposes such as customising content and advertising. See our Privacy Policy to learn more